Lisa is based in Tokyo as a managing editor and will be providing editorial coverage of all aspects of Japan’s prescription drug market for Scrip and the Pink Sheet, including company, market, pricing and regulatory developments, as well as helping to further expand our original content in the region through interviews and unique stories. In the longer term, the intention is for Lisa to support, along with the rest of the content team, our broader regional push towards more local-language content, use of multimedia, and thought leadership initiatives.
Lisa brings close to a decade of experience working in either international teams or reporting, writing and editing, including in broadcast media through an internship as a TV reporter in Canada. Most recently, she was covering another fast-moving, high-tech sector, IT, for ITmedia Enterprise in Japan, where several of her stories won quarterly “Best Content” awards and helped significantly expand readership.
Lisa holds an MA in Fine Art from Tokyo University of the Arts as well as a Master’s in Journalism from the University of King’s College in Halifax, Canada. She is native level bilingual in Japanese and English and also has conversational ability in Mandarin and French. Her interests and hobbies outside work include taking monochrome photos with digital/film cameras and visiting museums.
Latest From Lisa Takagi
Japan has granted to the first approval worldwide to Daiichi Sankyo’s dual EZH1/2 inhibitor valemetostat, for the treatment of adult T-cell leukemia/lymphoma. Taisho’s trivalent anti-TNFα nanobody ozoralizumab also received its global first approval, as part a large new batch of regulatory nods in the country.
Japan’s fast-track approval system for innovative drug candidates has marked its seventh year since launch, during which it has accepted 27 candidates with 13 of these moving to approval. But in recent years the system has faced a decreasing number of admitted candidates, this original infographic analysis shows.
AnGes has terminated R&D work on a DNA vaccine for COVID-19 and will now look at intranasal candidates with a US partner. Although the original project received funding from the Japanese government, a spike in related costs caused the Japanese firm's net loss to triple last year, and the decision represents the latest in a string of pipeline setbacks.
A controversial letter from two Japanese doctors' associations seemingly pressing regulators to approve Shionogi’s oral COVID-19 drug prompts a backlash from other physicians.
Novo Nordisk has filed for the approval of its hemophilia A/B contender concizumab in Japan, which could become the first market globally for the TFPI inhibitor. The company sees dosing convenience as a potential strong advantage in the market, where there are relatively few options for hemophilia B available.
Plus agreements involving Hansoh/GHDDI, BriaCell/UMBC, Novartis/UC Berkeley, NeoPhore/Memorial Sloan Kettering, GEn1E/UM-Baltimore, ValoTx/University of Helsinki and Sosei/Cancer Research UK.